{"title":"Biological properties and DNA nanomaterial biosensors of exosomal miRNAs in disease diagnosis","authors":"Zhikun Zhang, Md. Ahasan Ahamed and Dayong Yang","doi":"10.1039/D4SD00373J","DOIUrl":null,"url":null,"abstract":"<p >MicroRNAs (miRNAs) regulate gene expression and are important biomarkers in molecular diagnostics, prognosis, and personalized medicine. The miRNAs that are found within exosomes, also known as exo-miRs, have been shown to demonstrate increased levels of both abundance and stability. Thus, exo-miRs show potential as a reliable biomarker for further investigation. Due to the programmable nanostructures, biocompatibility, and excellent molecular recognition ability, biosensing platforms based on DNA nanomaterial are considered promising for detecting exo-miRs in clinical analysis, including cancer, neurodegenerative disorders, and infectious diseases. Although considerable advancements have been achieved in exo-miR-based testing, there are ongoing challenges in accurately detecting and analyzing multiple targets concurrently at low concentrations in complex biological samples. The primary focus of our research is to thoroughly analyze the biogenesis of exo-miRs, carefully assess their levels of expression in various clinical diseases, and comprehensively investigate their correlations with a wide range of diseases, including cancer, infection, and neurodegenerative disorders. We also examined recent progress in DNA nanomaterial-based detection methods for exo-miRs. This study explores the challenges and intricacies faced during the creation and execution of exo-miR tests within a clinical setting to diagnose diseases. The successful development and implementation of DNA nanomaterials for exo-miR detection can significantly revolutionize the early detection, monitoring, and management of various medical conditions, leading to enhanced healthcare outcomes.</p>","PeriodicalId":74786,"journal":{"name":"Sensors & diagnostics","volume":" 4","pages":" 273-292"},"PeriodicalIF":3.5000,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2025/sd/d4sd00373j?page=search","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sensors & diagnostics","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2025/sd/d4sd00373j","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}
引用次数: 0
Abstract
MicroRNAs (miRNAs) regulate gene expression and are important biomarkers in molecular diagnostics, prognosis, and personalized medicine. The miRNAs that are found within exosomes, also known as exo-miRs, have been shown to demonstrate increased levels of both abundance and stability. Thus, exo-miRs show potential as a reliable biomarker for further investigation. Due to the programmable nanostructures, biocompatibility, and excellent molecular recognition ability, biosensing platforms based on DNA nanomaterial are considered promising for detecting exo-miRs in clinical analysis, including cancer, neurodegenerative disorders, and infectious diseases. Although considerable advancements have been achieved in exo-miR-based testing, there are ongoing challenges in accurately detecting and analyzing multiple targets concurrently at low concentrations in complex biological samples. The primary focus of our research is to thoroughly analyze the biogenesis of exo-miRs, carefully assess their levels of expression in various clinical diseases, and comprehensively investigate their correlations with a wide range of diseases, including cancer, infection, and neurodegenerative disorders. We also examined recent progress in DNA nanomaterial-based detection methods for exo-miRs. This study explores the challenges and intricacies faced during the creation and execution of exo-miR tests within a clinical setting to diagnose diseases. The successful development and implementation of DNA nanomaterials for exo-miR detection can significantly revolutionize the early detection, monitoring, and management of various medical conditions, leading to enhanced healthcare outcomes.
微RNA(miRNA)可调控基因表达,是分子诊断、预后和个性化医疗的重要生物标志物。在外泌体中发现的 miRNA(也称为外miRs)已被证明在丰度和稳定性方面都显示出更高的水平。因此,外miRs显示出作为可靠生物标记物的潜力,有待进一步研究。基于 DNA 纳米材料的生物传感平台具有可编程纳米结构、生物相容性和出色的分子识别能力,因此被认为有望在癌症、神经退行性疾病和传染病等临床分析中检测外显子-miRs。虽然基于外显子-miR 的检测已取得了长足的进步,但在复杂的生物样本中同时准确检测和分析低浓度的多个靶点仍面临挑战。我们研究的主要重点是彻底分析外显子-miR 的生物发生,仔细评估它们在各种临床疾病中的表达水平,并全面研究它们与癌症、感染和神经退行性疾病等多种疾病的相关性。我们还研究了基于 DNA 纳米材料的外显子-miRs 检测方法的最新进展。本研究探讨了在临床环境中创建和执行外显子-miR 检测以诊断疾病所面临的挑战和错综复杂的问题。用于外显子-miR检测的DNA纳米材料的成功开发和实施将极大地改变各种疾病的早期检测、监测和管理,从而提高医疗保健效果。